54aafc79868f4b00075cb3a1_logo.jpg
Source: Canbiola, Inc.

Canbiola Appoints David Woycik, Jr. to its Corporate Advisory Board and Completes a 300% Increased Investment in its Duramed Division to Combat the Opioid Crisis


Adds Pharmaceutical and Business Operations Expertise with Key Relationships to Provide Growth Opportunities for Canbiola

HICKSVILLE, NY, May 06, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Canbiola, Inc. (OTCQB: CANB) (“Canbiola” or the “Company”), a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrate, announced today the appointment of Mr. David Woycik, Jr. to its Corporate Advisory Board. 

Canbiola Chief Executive Officer, Marco Alfonsi, commented, “We are thrilled to have Mr. Woycik join our Corporate Advisory Board. We look forward to his knowledge, advice and relationships in the pharmaceutical field as we explore expanding our CBD product portfolio and their awareness and distribution. In particular, Mr. Woycik, Jr.’s experience, exposure and relationships with the Armed Forces and Canine Companions for Independence and VetDogs of America which are both ripe for opportunities with CBD and Canbiola.”

Mr. David Woycik, Jr. stated, “I am extremely proud and honored to become a member of Canbiola’s Corporate Advisory Board. As the former Vice President and General Counsel of a major pharmaceutical company, PharmaFair, Inc., I fully appreciate the need for experienced and knowledgeable business men and women to assist this new and exciting company for greater success in the future. As a former pharmaceutical Executive, I was exposed to many FDA regulatory and sales and marketing issues which will help in the growth of Canbiola’s diverse product line and strategically assist Canbiola as it advances its business.”

Canbiola increased its investment in Duramed by 300% to continue the initial deployment of the sam®Pro 2.0 device to treat Chronic Pain and decrease/eliminate the crisis level use of Opioid-based Pain Medication for Workers Comp, Personal Injury, Wounded Warriors and Veterans. The sam®Pro 2.0 rollout offered to patients via its physician office program continues to ramp successfully and has dozens of clinics prescribing the sam®Pro 2.0 to treat Chronic Pain Patients to date.

About Canbiola,Inc.

Canbiola, Inc. (OTCQB: CANB) is a developer, manufacturer and seller of a variety of Cannabidiol (Hemp) based products such as oils, creams, moisturizers, chews, isolate, gel caps, and concentrates. Canbiola has developed its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states, but pure CBD products are legal in all 50 states.  Hemp CBD is the non-psychoactive component (No THC) used for treatment of pain, inflammation, and wellness programs.  For more information about Canbiola, Inc., please visit: https://canbiola.com.

Additionally, Canbiola’s wholly owned subsidiary Pure Health Products, based in Lacey, WA, is its prime development laboratory and production facility.  Canbiola’s Duramed division has recently initiated deployment of the proprietary durable medical device, sam®Pro 2.0, through its’ Physician network for the treatment of Workers Comp Patients, Personal Injury Patients, Wounded Warrior Care and Veterans via the application of the only FDA cleared wearable-active Ultrasound developed treatment device for in-home use to treat chronic pain and reduce or eliminate the use of opioid-based pain medication while accelerating the healing of musculoskeletal injuries.

Forward-Looking Statements

Forward-looking statements and risks and uncertainties discussed in this letter contain forward-looking statements. The words "anticipate," "believe," "estimate," "may," "intend," "expect," and similar expressions identify such forward-looking statements. Expected, actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. Forward-looking statements are subject to a number of risks and uncertainties, including but not limited to, risks and uncertainties associated with, among other things, the impact of economic, competitive, and other factors affecting our operations, markets, products, and performance. The matters discussed herein should not be construed in any way, shape or manner of our future financial condition or stock price.

Follow Canbiola on: 

Twitter @CanbiolaHealth

Instagram @canbiola.inc or @canbiola_cbd or @canbiola_medical_cbd


Investors and Media:

IR@canbiola.com

(516) 595-9544